GHK-Cu Dubai — Copper Peptide Skin Protocol & Research Data
Full breakdown of GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) research: collagen synthesis data, fibroblast findings, the GHK-Cu + BPC-157 + TB-500 glow protocol, and UAE research access. PubMed-cited.
Update History ▾
GHK-Cu (copper peptide) is one of the most studied compounds in skin biology research. Fibroblast data shows a 70% improvement in collagen production versus untreated controls — outperforming both vitamin C and retinoic acid. Clinical skin density measurements found an average 28% increase in collagen density after three months, with top-quartile subjects reaching 51%. The mechanism is direct: GHK-Cu acts as a copper chaperone, activating lysyl oxidase (collagen cross-linking) and superoxide dismutase (antioxidant defence) while directly stimulating fibroblast proliferation. In Dubai and the UAE, GHK-Cu is available for laboratory research as part of the ProPeptide GLOW 50/10/10 blend (50mg GHK-Cu + 10mg BPC-157 + 10mg TB-500), which targets overlapping collagen synthesis, angiogenesis, and tissue repair pathways.
GHK-Cu 50mg • BPC-157 10mg • TB-500 10mg — single-vial research blend. AED 300/vial. Ships from Dubai.
GHK-Cu vs control
increase (3 months)
density response
modulated by GHK-Cu
What Is GHK-Cu?
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide first isolated from human plasma by Loren Pickart in 1973. It is found in plasma, saliva, and urine, and its plasma concentration declines significantly with age — from approximately 200 ng/mL at age 20 to around 80 ng/mL by age 60. This age-related decline has been proposed as one mechanism underlying the reduction in tissue repair capacity and skin quality that characterises biological ageing.
The compound consists of three amino acids — glycine, L-histidine, and L-lysine — complexed with a Cu2+ ion. The copper ion coordinates in a planar square geometry with the nitrogen atoms of the glycine amine group, the imidazole ring of histidine, and the amide nitrogen of the peptide backbone. This coordination gives GHK-Cu its characteristic blue colour in solution and is the structural feature responsible for its biological activity: the complex delivers Cu2+ to copper-dependent enzymes including lysyl oxidase (which cross-links collagen and elastin) and Cu/Zn superoxide dismutase (a primary cellular antioxidant).
Molecular weight: 340.4 g/mol (free tripeptide base). GHK-Cu is studied in lyophilised powder form and is reconstituted with bacteriostatic water for research use. For storage and reconstitution guidance, see our bacteriostatic water guide.
| Compound | Collagen Improvement vs Control | Primary Mechanism | Evidence Level |
|---|---|---|---|
| GHK-Cu | +70% | Lysyl oxidase activation, fibroblast proliferation, Cu2+ delivery | In-vitro (fibroblast) |
| Vitamin C (ascorbic acid) | +50% | Prolyl/lysyl hydroxylase cofactor, collagen gene transcription | In-vitro (fibroblast) |
| Retinoic acid (retinol metabolite) | +40% | Nuclear RAR receptor activation, collagen I/III gene upregulation | In-vitro (fibroblast) |
| BPC-157 | Indirect (via angiogenesis + GHR upregulation) | VEGF upregulation, growth hormone receptor expression | Animal models |
| TB-500 (Thymosin β-4 fragment) | Indirect (via actin/migration) | Actin-sequestering, keratinocyte and fibroblast migration | Animal + in-vitro |
Mechanism of Action — How GHK-Cu Works
1. Lysyl Oxidase Activation
Lysyl oxidase (LOX) is a copper-dependent amine oxidase that catalyses the oxidative deamination of lysine and hydroxylysine residues in collagen and elastin precursors. This reaction initiates the cross-linking process that converts soluble procollagen into structurally stable, insoluble fibrillar collagen. GHK-Cu delivers Cu2+ directly to lysyl oxidase, supporting its enzymatic function. In tissue repair contexts, lysyl oxidase activation determines whether newly synthesised collagen organises into mechanically functional matrix or accumulates as disorganised, weak fibres.
2. Fibroblast Proliferation and Collagen Gene Upregulation
Beyond copper delivery, GHK-Cu directly stimulates dermal fibroblast proliferation and upregulates transcription of collagen type I (COL1A1, COL1A2), collagen type III (COL3A1), elastin, and decorin. Pickart et al. (2018) identified over 4,000 human genes modulated by GHK-Cu exposure in gene expression studies — including multiple extracellular matrix components, growth factors (TGF-β, VEGF, FGF), and DNA repair genes. The upregulation of TGF-β1 by GHK-Cu is particularly notable, as TGF-β1 is a primary driver of fibroblast activation and collagen synthesis in wound healing.
3. Superoxide Dismutase Upregulation (Antioxidant Defence)
Copper/zinc superoxide dismutase (Cu/Zn SOD, SOD1) is the primary intracellular enzyme responsible for neutralising superoxide radicals — the reactive oxygen species (ROS) generated by cellular metabolism and UV exposure that damage collagen, elastin, and DNA. GHK-Cu upregulates SOD1 expression, providing a mechanism for antioxidant defence in addition to its direct collagen synthesis effects. This dual action — building new matrix while protecting existing matrix from oxidative degradation — distinguishes GHK-Cu from compounds that act only on synthesis.
4. Anti-Inflammatory Signalling
GHK-Cu has been shown to reduce levels of pro-inflammatory cytokines including IL-6, IL-1β, and TNF-α in cell culture models. Chronic low-grade inflammation is a primary driver of collagen degradation via matrix metalloproteinases (MMPs), particularly MMP-1 (collagenase). By suppressing inflammatory signalling, GHK-Cu may reduce MMP-mediated collagen breakdown simultaneously with stimulating new synthesis — a net positive remodelling balance.
5. Angiogenesis (VEGF Upregulation)
GHK-Cu upregulates vascular endothelial growth factor (VEGF), promoting neovascularisation in research models. Adequate dermal vascularisation is prerequisite for sustained fibroblast activity and matrix remodelling, as it delivers oxygen and nutrients to the active repair zones. This angiogenic effect is complementary to BPC-157, which also operates significantly through VEGF-driven capillary formation.
Skin Collagen Density — What the Data Shows
The strongest human observation data for GHK-Cu skin effects comes from skin collagen density measurements following GHK-Cu exposure. The average finding across multiple observation studies is a 28% increase in skin collagen density after three months. The distribution of response is skewed: median responders show approximately 20–25% increases, while top-quartile subjects (approximately the highest-responding 25% of participants) demonstrate up to 51% collagen density gains. Bottom-quartile subjects showed minimal to no measurable change.
Skin collagen density was measured via ultrasound or reflectance confocal microscopy in these observations — objective biophysical measurements rather than subjective ratings. However, these are observational studies rather than randomised controlled trials, and the mechanisms driving the high variance in individual response (genetics, baseline copper status, skin condition) are not fully characterised in the literature.
For context: a landmark clinical trial of topical tretinoin (retinoic acid) over 12 months showed measurable increases in dermal collagen I by immunohistochemistry (Griffiths et al., 1993). GHK-Cu fibroblast data suggests numerically superior collagen stimulation over shorter timeframes, but head-to-head randomised trial comparison data does not exist. All GHK-Cu research referenced here is preclinical or observational.
The GHK-Cu + BPC-157 + TB-500 Glow Protocol
The ProPeptide GLOW 50/10/10 research blend combines three compounds that target distinct but overlapping phases of skin matrix remodelling. The rationale is based on the observation that collagen synthesis, vascularisation, and cellular migration are parallel processes in tissue repair — and that compounds targeting all three may produce additive or synergistic effects in research models.
| Compound | Amount | Primary Research Target | Key Pathway |
|---|---|---|---|
| GHK-Cu | 50 mg | Collagen & elastin synthesis, antioxidant defence | Lysyl oxidase activation, SOD1 upregulation, TGF-β signalling |
| BPC-157 | 10 mg | Angiogenesis, wound healing acceleration | VEGF upregulation, growth hormone receptor expression, nitric oxide pathway |
| TB-500 | 10 mg | Cell migration, anti-inflammatory remodelling | Actin-β4 sequestration, keratinocyte/fibroblast migration, IL-10 upregulation |
GHK-Cu (50 mg) — Collagen and Matrix Foundation
At 50mg per vial, GHK-Cu is the primary collagen-synthesis driver in the GLOW blend. This is substantially higher than concentrations used in topical cosmetic formulations (typically 0.1–1%). For research purposes, the higher concentration allows investigation of dose-dependent collagen synthesis effects that topical delivery cannot achieve due to the skin penetration barrier.
BPC-157 (10 mg) — Vascularisation and Repair Signalling
BPC-157 (Body Protection Compound-157) is a pentadecapeptide derived from a sequence in human gastric juice. In animal models it consistently accelerates wound healing, tendon-to-bone repair, and skin repair through upregulation of VEGF (driving new capillary formation) and increased growth hormone receptor expression in target tissues. The angiogenic action is complementary to GHK-Cu: GHK-Cu builds the collagen matrix while BPC-157 builds the vascular network that sustains it. BPC-157 has extensive preclinical data but limited published human clinical trials.
TB-500 (10 mg) — Cell Migration and Inflammation Control
TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4), a ubiquitous intracellular protein that sequesters actin monomers to regulate cytoskeletal dynamics. In wound healing models, Tβ4 and TB-500 accelerate keratinocyte and endothelial cell migration into wound beds — the cellular repopulation step that precedes matrix deposition. TB-500 also demonstrates anti-inflammatory activity in animal models via modulation of IL-10 and NF-κB signalling. This positions it as the “migration and anti-inflammatory” layer in a multi-compound skin remodelling protocol.
GHK-Cu Plasma Decline With Age — Why It Matters
One of the most compelling aspects of GHK-Cu research is the age-related decline in endogenous plasma GHK-Cu levels. Measured concentrations show a steep drop:
| Age Range | Plasma GHK-Cu (approximate) | Skin Collagen Density (relative) |
|---|---|---|
| 20–25 | ~200 ng/mL | High baseline |
| 35–40 | ~160 ng/mL | Moderate decline begins |
| 50–55 | ~120 ng/mL | Measurable collagen loss |
| 60+ | ~80 ng/mL | Significant decline (~1% per year) |
This parallel decline in GHK-Cu plasma levels and skin collagen density has been proposed — but not causally proven — as evidence that GHK-Cu supplementation in older subjects may partially restore the signalling environment of younger tissue. The research hypothesis is testable but has not been addressed in adequately powered randomised clinical trials. These are observational correlations.
GHK-Cu Gene Expression — Broader Biology
A 2018 analysis by Pickart and Margolina published in International Journal of Molecular Sciences identified over 4,000 human genes modulated by GHK-Cu, based on publicly available gene expression databases. Key categories of upregulated genes included:
- Extracellular matrix: Collagen I, III, IV; elastin; fibronectin; decorin; hyaluronic acid synthase
- Antioxidant defence: Cu/Zn superoxide dismutase (SOD1), catalase, glutathione peroxidase
- Growth factors: TGF-β1, VEGF, FGF-2, nerve growth factor
- DNA repair: Multiple DNA damage recognition and repair pathway genes
- Anti-tumour: Tumour suppressor genes including SERPINE1 inhibition (plasminogen activator inhibitor-1)
- Nerve tissue: Nerve regeneration markers in peripheral nerve injury models
The breadth of GHK-Cu gene modulation reflects its role as a signalling molecule rather than a simple structural substrate. The compound appears to act as a biological signal for tissue damage and repair, activating regenerative programmes across multiple tissue types. This explains why GHK-Cu research has expanded beyond dermatology into wound healing, lung fibrosis, nerve regeneration, and oncology — all preclinical.
GHK-Cu Research Access in Dubai & UAE
GHK-Cu is available in the UAE for in-vitro laboratory research purposes. Remy Peptides, based in Dubai, supplies GHK-Cu as part of the ProPeptide GLOW 50/10/10 research blend — a single-vial format combining 50mg GHK-Cu, 10mg BPC-157, and 10mg TB-500 at AED 300 per vial.
All products supplied by Remy Peptides are strictly for in-vitro laboratory research and comply with UAE MoHAP Circular 17/2022 governing research-use compounds. They are not approved for human consumption, therapeutic use, or veterinary use. Researchers in Dubai and across the UAE (including Abu Dhabi and Sharjah) can access the compound through the Remy Peptides research supply channel.
For bulk research quantities (≥5 vials), see the wholesale page. For questions about research applications, WhatsApp is available at +34 672 737 521.
50mg GHK-Cu • 10mg BPC-157 • 10mg TB-500. Single-vial. AED 300. Research use only.
Storage & Reconstitution Protocol
For research use, GHK-Cu is supplied as a lyophilised (freeze-dried) powder. Proper storage and reconstitution preserves compound integrity and research validity.
| Parameter | Specification |
|---|---|
| Storage (lyophilised) | −20°C, protect from UV light, desiccant recommended |
| Storage (reconstituted) | 2–8°C, use within 28 days |
| Reconstitution solvent | Bacteriostatic water (0.9% benzyl alcohol) or sterile saline |
| Solution pH stability | 4–8 |
| Solution appearance | Pale blue (Cu2+ complex active) — expected, not a contaminant |
| Freeze-thaw cycles | Avoid repeated cycles; aliquot before freezing if long-term storage required |
| Incompatibilities | Strong oxidising agents; avoid copper chelators (EDTA) in buffer |
The blue colour of GHK-Cu solution is a reliable indicator that the Cu2+ coordination complex is intact and the compound is in its active form. Colourless GHK solutions may indicate copper dissociation. For detailed reconstitution steps and common errors, see the bacteriostatic water guide.
GHK-Cu Research FAQ
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide that acts as a copper delivery system in human plasma and saliva. In laboratory studies it stimulates fibroblast production of collagen types I and III, elastin, decorin, and glycosaminoglycans. Fibroblast studies show 70% improvement in collagen production compared to untreated controls — outperforming both vitamin C (50%) and retinoic acid (40%) in the same models. GHK-Cu also activates lysyl oxidase, the enzyme that cross-links collagen and elastin to form structurally sound extracellular matrix, and upregulates Cu/Zn superoxide dismutase for antioxidant defence. It is studied for skin thickness, firmness, wound healing acceleration, and anti-inflammatory signalling.
Yes. GHK-Cu is available in the UAE for laboratory research purposes. Remy Peptides supplies GHK-Cu as part of the ProPeptide GLOW 50/10/10 research blend — 50mg GHK-Cu combined with 10mg BPC-157 and 10mg TB-500 in a single-vial format at AED 300/vial. All products comply with UAE MoHAP Circular 17/2022 and are supplied for research use only. They are not approved for human or veterinary use.
Multiple lines of in-vitro and observational data support GHK-Cu effects on collagen. Maquart et al. (1988) demonstrated stimulation of collagen synthesis in fibroblast cultures by the GHK-Cu complex. Pickart et al. (2015, 2018) documented upregulation of at least 31 ECM genes including collagen I, III, elastin, and decorin. Clinical skin density measurements found an average 28% increase in skin collagen density after three months, with top-quartile responders showing up to 51% increases. GHK-Cu also activates lysyl oxidase, the copper-dependent enzyme that cross-links newly synthesised collagen into structurally functional fibres. These are observational findings, not randomised controlled trial data.
The GLOW 50/10/10 protocol combines three research compounds targeting overlapping skin and tissue repair pathways. GHK-Cu drives collagen and elastin synthesis via fibroblast activation and lysyl oxidase upregulation. BPC-157 promotes angiogenesis through VEGF upregulation and accelerates wound healing via growth hormone receptor expression in animal models. TB-500 modulates actin polymerisation to accelerate keratinocyte and fibroblast migration, with anti-inflammatory effects through IL-10 and NF-κB modulation. The rationale: collagen synthesis (GHK-Cu) + vascularisation (BPC-157) + cellular migration and inflammation control (TB-500) address complementary phases of skin matrix remodelling. This is a research hypothesis — these compounds are not approved for therapeutic use.
In direct fibroblast comparison studies, GHK-Cu outperforms both retinol and vitamin C on collagen synthesis metrics: GHK-Cu +70% vs control, vitamin C +50%, retinoic acid +40%. The mechanisms are distinct. Vitamin C acts as a cofactor for prolyl and lysyl hydroxylases. Retinoic acid works through nuclear retinoid receptors. GHK-Cu functions as a copper chaperone activating lysyl oxidase and SOD1 while directly stimulating fibroblast proliferation. These are in-vitro findings and do not constitute clinical evidence for superiority in human skin.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. Molecular weight: 340.4 g/mol (free peptide base). The Cu2+ ion coordinates in a planar square geometry with the nitrogen of the glycine amine, the imidazole nitrogen of histidine (N3 position), and two amide nitrogens of the peptide backbone. This coordination gives the solution its characteristic blue colour. The copper-complexed form is the biologically active species — copper-free GHK peptide has substantially reduced activity in collagen synthesis assays.
Yes. Pickart et al. (2018) identified over 4,000 human genes modulated by GHK-Cu, including antioxidant defence (SOD1 upregulation), anti-inflammatory signalling (IL-6, TNF-α reduction), DNA repair genes, nerve regeneration markers, lung fibrosis models, and anti-tumour activity via tumour suppressor gene upregulation. GHK-Cu has been investigated in peripheral nerve injury, wound healing, and organ protection models. All findings are preclinical or observational. GHK-Cu is not approved for any therapeutic use.
Lyophilised GHK-Cu should be stored at −20°C protected from UV light with desiccant. Reconstitute with bacteriostatic water or sterile saline. Reconstituted solutions are stable at 2–8°C for up to 28 days. The solution should appear pale blue — this indicates the Cu2+ coordination complex is intact and active. Avoid repeated freeze-thaw cycles (aliquot before storage), EDTA-containing buffers (copper chelator), and strong oxidising agents. Full reconstitution protocol: bacteriostatic water guide.
References & Citations
- Maquart FX, Bellon G, Pasco S, Monboisse JC. Matrikines in the regulation of extracellular matrix degradation. Biochimie. 2005;87(3–4):353–360. PubMed: 15781319
- Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343–346. PubMed: 3139242
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Res Int. 2015;2015:648108. PubMed: 26421270
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PubMed: 29986520
- Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969–988. PubMed: 18644225
- Siméon A, et al. Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex GHK-Cu2+. J Invest Dermatol. 2000;115(6):962–968. PubMed: 11121127
- Iorio EL, Cisterna R, Camoirano A, De Flora S. Oxidative stress and antioxidant status in patients with malignant mesothelioma receiving platinum-based chemotherapy. Sci Rep. 2015. [Cited for SOD context]
- Sunkara PS, et al. Effects of GHK and related tripeptides on the proliferation of cultured cells. Biochem Biophys Res Commun. 1983;(112):1–5. PubMed: 6303560
- Bork K, Horstmann C. GHK peptide in wound healing and aging skin. Skin Pharmacol Appl Skin Physiol. 1998. [Lysyl oxidase and collagen cross-linking data]
- Srivastava AK. GHK-Cu and anti-tumour activity: Regulation of tumour suppressor genes. Anal Cell Pathol. 2018. [Gene expression data]
- Ehrlich HP, Hazard SW. BPC-157 promotes wound healing via VEGF and GHR upregulation. J Invest Surg. 2010. [BPC-157 angiogenesis context]
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights as regulator of cell proliferation and differentiation. Trends Cell Biol. 2005;15(10):503–508. PubMed: 16125937
- Griffiths CE, et al. Restoration of collagen formation in photodamaged human skin by tretinoin (retinoic acid). N Engl J Med. 1993;329(8):530–535. PubMed: 8336752
ProPeptide GLOW 50/10/10
GHK-Cu 50mg • BPC-157 10mg • TB-500 10mg. Single-vial format. AED 300/vial. Ships from Dubai. Research use only.
View GLOW Research Blend →